Join OncoGenerix Webinar on October 20 Tokens are on sale
Welcome to OncoGenerix Token,

Invest in a real business,
not just an idea

We are offering to qualified investors a limited pre-IPO investment opportunity in an operational injectable pharmaceuticals factory

Invest now
Video presentation
Invest now
OncoGenerix

Anticipated Token Price Growth

ONGX Token Value
Cumulative Growth
Annual Return
OGinvest Value
2020
$0.17
0%
0%
-
0
2021
$0.2
18%
18%
$100mm
0
2022
$0.23
35%
18%
$115mm
0
2023
$0.27
59%
20%
$135mm
0
2024
$0.33
94%
24%
$165mm
0
IPO Range
$0.45
165%
33%
$225mm
$0.9
429%
86%
$450mm
0
0

Location

Production Plant
Corporate Office
OncoGenerix Production Plant 157000, No.7, Dongxu Road, Hailin, Mudanjiang City, Heilongjiang Province People’s Republic of China
State-of-the-art manufacturing facility offers technical transfer, process development, process scale up, equipment and process validation, formulation, filling, lyophilization, inspection, integrity testing, labeling and packaging.
Current Production Area
19,662 m2
Future Expansion Space
15,543 m2
Total Site Area
39,870 m2
OGInvest Limited
US Representative Office
6046 Cornerstone Court W, Suite 155
San Diego, CA 92121
OGInvest Limited is a special purpose entity investor and shareholder of Onco Generix Co. Ltd., the owner of the OncoGenerix manufacturing facility.
Location 3
State-of-the-art manufacturing facility offers technical transfer, process development, process scale up, equipment and process validation, formulation, filling, lyophilization, inspection, integrity testing, labeling and packaging.
Current Production Area
19,662 m2
Future Expansion Space
15,543 m2
Total Site Area
39,870 m2

About OncoGenerix

Project Overview

OncoGenerix is the next generation provider of compliant and high-quality contract manufacturing services for injectable products.

OncoGenerix offers a fully integrated suite of contract manufacturing services including technical transfer, process development, scale-up, equipment and process validation, formulation, filling, lyophilization, inspection, labeling, and packaging.

Meet our

Strategic Partners

SPH is one of the largest vertically-integrated and diversified pharmaceutical group in China. The company provides leading healthcare services in: R&D, Manufacturing, Distribution and Retail.

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions.

NYSC:SCR R&D — driven pharmaceutical company. It has been ranked amongst the top 100 pharmaceutical companies in China

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology

Pharma Resources (Germany) GmbH operates as a contract research organization that offers research, development, and manufacturing of small molecules.

Beloteca, Inc. is focused on the development of pharmaceutical products with an emphasis on sterile pharmaceutical products

Brick42 is a group of talented international business developers focused on guiding early stage and disruptive technologies into the market

Token

Offer Structure

Offered for sale is 100% of SPV, which, through intermediaries, possesses ownership of up to 15% in OncoGenerix production facility.
Token Name ONGX
Price Per Token $0.17
Minimum Investment $100
Tokens Per Share 1000
Token Standard ERC-20
For Sale up to 15% of OG Factory
Targeted IRR 33%
Targeted Equity Multiple 2.65
Targeted Minimum Return 18%
Targeted Investment Period 4-5y
Your browser does not support SVG Your browser does not support SVG
OncoGenerix

Timeline

The OncoGenerix timeline provides for you with a transparent view of our specific phases and important milestones of accomplishment.

Stage 1

EU GMP certificate has been granted to Oncogenerix. Factory brings first approved product for sale in EU Market. At the same time Factory is engaged in Technical Transfer and Product Approval procedures for the next 3 products. No material revenues from commercial production are expected during 2020.

In progress
2020

Stage 1 - description

EU GMP certificate has been granted to Oncogenerix. Factory brings first approved product for sale in EU Market. At the same time Factory is engaged in Technical Transfer and Product Approval procedures for the next 3 products. No material revenues from commercial production are expected during 2020.

Stage 2

During 2021 Factory will start commercial production of the first product in EU. Factory will pass Chinese GMP inspection and start sales of the first product in China.

Factory is forecasted to get EU approvals for 3 more products to start commercial production of these products for in EU by the end of the year. Moderate revenue for the year will partially cover Factory costs.

Upcoming
2021

Stage 2 - description

During 2021 Factory will start commercial production of the first product in EU. Factory will pass Chinese GMP inspection and start sales of the first product in China.

Factory is forecasted to get EU approvals for 3 more products to start commercial production of these products for in EU by the end of the year. Moderate revenue for the year will partially cover Factory costs.

Stage 3

In 2022 Factory is expected to pass Chinese inspection for 3 more products and start commercial production for capacious China market. The Factory will also launch sales of a high value product in some Asia and Latin America countries, while this product is still under patent protection in most of the world. The Factory is expected to get US FDA approval for entering US market with one of it’s products. By the end of 2022 the Factory is anticipated to reach operational break-even point.

Upcoming
2022

Stage 3 - description

In 2022 Factory is expected to pass Chinese inspection for 3 more products and start commercial production for capacious China market. The Factory will also launch sales of a high value product in some Asia and Latin America countries, while this product is still under patent protection in most of the world. The Factory is expected to get US FDA approval for entering US market with one of it’s products. By the end of 2022 the Factory is anticipated to reach operational break-even point.

Stage 4

In 2023 Factory is expected to get EU and US FDA approvals and start sales of 3 more high-value products in these markets. The Factory plans also to start 2 more products in China market and ramp up sales of the earlier launched products. New products can be added to the pipeline depending on capacity and arising opportunity. Growing sales should lead to substantial positive total cash flow by the end of the year.

Upcoming
2023

Stage 4 - description

In 2023 Factory is expected to get EU and US FDA approvals and start sales of 3 more high-value products in these markets. The Factory plans also to start 2 more products in China market and ramp up sales of the earlier launched products. New products can be added to the pipeline depending on capacity and arising opportunity. Growing sales should lead to substantial positive total cash flow by the end of the year.

Stage 5

While new pipeline may certainly exist for new products, OncoGenerix’s business plan for 2024 is focused on forecastable products basket and operating excellence. The projected profit level for 2024 will create alluring exit prospects for financial investors.

Upcoming
2024

Stage 5 - description

While new pipeline may certainly exist for new products, OncoGenerix’s business plan for 2024 is focused on forecastable products basket and operating excellence. The projected profit level for 2024 will create alluring exit prospects for financial investors.

Meet our

Executive Leadership

The executives at OncoGenerix are proven industry leaders. Their wide range of expertise, skills, and knowledge spans across many business disciplines including: pharmaceuticals, healthcare, finance, law, and technology

Corporate Leadership
Oleksandr Zabudkin
CEO
Anders Blom
Director of Finance and investment
Julian Aleksov
Director for Strategy and Business Development
Ramana Reddy Muchumari
Director of Quality & RA
Haixing Zheng
Director of Non-GMP Local External Affairs
Yanchao Liang
HR Manager
Yu Liu
Legal Counsel
Yingqi Zhu
Sales Manager
Weilin Ji
Accounting Manager
Li Chen
Quality Management
Jian Kang
Head of Human Resources
Bill Allan
Engineering Manager
Jin Wang
Deputy Director of Quality & RA
Abrar Jagirdar
Production Quality Control
Long Zhao
Engineer
Thomas Paul
Quality Control Manager
We always look forward to answering your questions

Contact us

Begin your new investment opportunity with OncoGenerix today!

contact us
Your browser does not support SVG Your browser does not support SVG Your browser does not support SVG Your browser does not support SVG
We always look forward to answering your questions

Contact us

Begin your new investment opportunity with OncoGenerix today!

Request for Private Deal

We are open to discuss special terms with investors looking to place over $250,000

contact-us-success-img

Your message has been successfully sent